8 results about "Hbv genotype" patented technology

The invention discloses a hepatitis B virus monoclonal neutralizing antibody SY-4 as well as preparation and application thereof. The hepatitis B virus monoclonal neutralizing antibody is SY-4 and consists of a heavy chain and a light chain paired with the heavy chain, the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the heavy chain of the SY-4 are DFSFSSHA, ISSYDGGTT and AKEGNAFRYFGWLPDYQYFGMDV in sequence, and the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the light chain of the SY-4 are QRINSRY, AAS and QQYGNSPLCS in sequence. The hepatitis B virus monoclonal neutralizing antibody SY-4 provided by the invention is an HBV neutralizing antibody, has ADCP activity, can crossly recognize various HBV genotypes HBsAg, has a good biological function, and provides a new candidate antibody for prevention and treatment of hepatitis B virus.

The invention discloses a monoclonal antibody aiming at hepatitis B virus HBsAg as well as preparation and application of the monoclonal antibody. The monoclonal antibody is composed of SY-1, SY-2, SY-3, SY-5, SY-6, SY-7, SY-8, SY-9, SY-10, SY-11, SY-13, SY-14, SY-15, SY-16, SY-17, SY-18, SY-19, SY-20, SY-21, SY-22, SY-33, SY-34, SY-36, SY-37, SY-38, SY-39, SY-40, SY-41, SY-43, SY-44, SY-45, SY-46, SY-47, SY-48, SY-49 and SY-. The monoclonal antibody is composed of SY-1, SY-2, SY-3, SY-48, SY-49 and SY-. The monoclonal antibody obtained through screening is high in HBsAg binding capacity and has multiple biological functions and the capacity of recognizing different HBV genotypes.

Isolated polynucleotides and polypeptides, and hepatitis B virus (HBV) vaccines comprising the same. Viral vectors for expressing such polypeptides, and which may be used in HBV vaccines, as well as methods of protecting a subject from HBV infection and methods of treating HBV in a subject comprising administering the polypeptides, vectors, or vaccines. Methods of designing and producing an HBV vaccine comprising designing vaccine antigens to cover the diversity within a geographic area using an antigen amino acid sequence that efficiently covers the epitopes in the HBV genotypes present in the geographic area.

The invention discloses a hepatitis B virus monoclonal neutralizing antibody SY-23 as well as preparation and application thereof. The hepatitis B virus monoclonal neutralizing antibody disclosed by the invention is SY-23 and consists of a heavy chain and a light chain paired with the heavy chain; the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the heavy chain of the SY-23 are GGTFRSYG, IVPIFGIS and VRGGAVAGAGSAGEGIFDY in sequence, and the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the light chain of the SY-23 are QSVSNN, GAS and QQHHSWPPFT in sequence. The hepatitis B virus monoclonal neutralizing antibody SY-23 provided by the invention is an HBV neutralizing antibody, has ADCP activity, can crossly recognize various HBV genotypes HBsAg, has a good biological function, and provides a new candidate antibody for prevention and treatment of hepatitis B virus.

The application belongs to the technical field of hepatitis B virus detection, and particularly relates to an HBV RNA capture probe, a biosensor and a detection system, the nucleotide sequence of the capture probe is as shown in SEQ ID NO. 5-8, the HBV RNA capture probe is anchored and combined with an electrochemical biosensor, the detection sensitivity is improved through the amplification effect of the circuit, efficient and accurate detection of HBV RNA is realized, the HBV RNA capture probe can cover all HBV genotypes and subtypes, and the coverage is high; the HBV RNA capture probe has strong combination specificity with HBV RNA, and cross-reaction is avoided; the HBV RNA capture probe has an effective signal amplification mechanism, and the detection sensitivity is improved; the operation is simple and rapid, and the HBV RNA capture probe is suitable for clinical batch detection.

The invention discloses a hepatitis B virus monoclonal neutralizing antibody SY-25 as well as preparation and application thereof. The hepatitis B virus monoclonal neutralizing antibody is SY-25 and consists of a heavy chain and a light chain paired with the heavy chain, the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the heavy chain of the SY-25 are SDSVSRGSYH, MQNSGHT and GRVGHDFWGGYLRFDYNTDV in sequence, and the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the light chain of the SY-25 are TGAVTSGHS, DTS and LLSYSGLRV in sequence. The hepatitis B virus monoclonal neutralizing antibody SY-25 provided by the invention is an HBV neutralizing antibody, has ADCP activity, can crossly recognize various HBV genotypes HBsAg, has a good biological function, and provides a new candidate antibody for prevention and treatment of hepatitis B virus.

The present invention provides methods and compositions for the treatment of HBV. Disclosed is an HBcAg particle comprising HBV core proteins from at least two different HBV genotypes and a vaccine vector comprising a nucleotide sequence having > = 90% sequence identity to SEQ ID NO: 5. Corresponding pharmaceutical compositions and their use in therapy, in drug preparation and in methods of vaccination are disclosed. The vaccination method comprises administering to a human (i) a first dose and (ii) a second dose of HBcAg particles and HBsAg, and (iii) a dose of a vaccine vector that expresses HBsAg from HBV genotype A, HBcAg from HBV genotype D, HBsAg having > = 90% sequence identity to SEQ ID NO: 7, HBcAg having > = 90% sequence identity to SEQ ID NO: 8 or 17, and an RT domain having > = 90% sequence identity to SEQ ID NO: 9.

The invention belongs to the technical field of hepatitis B virus detection, and particularly relates to an HBV RNA capture probe, a biosensor and a detection system, the nucleotide sequence of the capture probe is as shown in SEQ ID NO.5-8, the HBV RNA capture probe and the electrochemical biosensor are anchored and combined, the detection sensitivity is improved through the circuit amplification effect, efficient and accurate detection of HBV RNA is achieved, and the detection sensitivity is improved. The HBV RNA capture probe can cover all HBV genotypes and subtypes, and the coverage degree is high; the HBV RNA capture probe is high in binding specificity with HBV RNA, and cross reaction is avoided; an effective signal amplification mechanism is provided, and the detection sensitivity is improved; the method is simple and rapid to operate and suitable for clinical batch detection.